JP4791355B2 - 抗腫瘍活性を有するカンプトテシンの７−イミノ誘導体 - Google Patents

抗腫瘍活性を有するカンプトテシンの７−イミノ誘導体 Download PDF

Info

Publication number
JP4791355B2
JP4791355B2 JP2006507637A JP2006507637A JP4791355B2 JP 4791355 B2 JP4791355 B2 JP 4791355B2 JP 2006507637 A JP2006507637 A JP 2006507637A JP 2006507637 A JP2006507637 A JP 2006507637A JP 4791355 B2 JP4791355 B2 JP 4791355B2
Authority
JP
Japan
Prior art keywords
compound
formula
group
pharmaceutical composition
linear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006507637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520807A5 (https=
JP2006520807A (ja
Inventor
サブリナ・ダッラヴァッレ
セルジョ・ペンコ
クラウディオ・ピサーノ
フランコ・ツニーノ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Istituto Nazionale per lo Studio e la Cura die Tumori
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale per lo Studio e la Cura die Tumori, Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Istituto Nazionale per lo Studio e la Cura die Tumori
Publication of JP2006520807A publication Critical patent/JP2006520807A/ja
Publication of JP2006520807A5 publication Critical patent/JP2006520807A5/ja
Application granted granted Critical
Publication of JP4791355B2 publication Critical patent/JP4791355B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2006507637A 2003-03-17 2004-03-10 抗腫瘍活性を有するカンプトテシンの７−イミノ誘導体 Expired - Fee Related JP4791355B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/388,587 US7105492B2 (en) 1999-03-09 2003-03-17 Camptothecin derivatives having antitumor activity
US10/388,587 2003-03-17
PCT/IT2004/000118 WO2004083214A1 (en) 2003-03-17 2004-03-10 7-imino derivatives of camptothecin having antitumor activity

Publications (3)

Publication Number Publication Date
JP2006520807A JP2006520807A (ja) 2006-09-14
JP2006520807A5 JP2006520807A5 (https=) 2007-05-10
JP4791355B2 true JP4791355B2 (ja) 2011-10-12

Family

ID=33029646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006507637A Expired - Fee Related JP4791355B2 (ja) 2003-03-17 2004-03-10 抗腫瘍活性を有するカンプトテシンの７−イミノ誘導体

Country Status (19)

Country Link
US (2) US7105492B2 (https=)
EP (1) EP1603919B1 (https=)
JP (1) JP4791355B2 (https=)
KR (1) KR101174112B1 (https=)
CN (1) CN100372855C (https=)
AR (1) AR043620A1 (https=)
AT (1) ATE417851T1 (https=)
AU (1) AU2004222044B2 (https=)
BR (1) BRPI0408380A (https=)
CA (1) CA2517450C (https=)
CY (1) CY1108890T1 (https=)
DE (1) DE602004018468D1 (https=)
DK (1) DK1603919T3 (https=)
ES (1) ES2319293T3 (https=)
PL (1) PL1603919T3 (https=)
PT (1) PT1603919E (https=)
SI (1) SI1603919T1 (https=)
TW (1) TWI341840B (https=)
WO (1) WO2004083214A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
ITRM20030344A1 (it) * 2003-07-14 2005-01-15 Ist Naz Stud Cura Dei Tumori 7-n-poliamminoalchil(ossi)imminometilcamptotecine recanti gruppi protettivi.
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
US8975248B2 (en) * 2004-12-15 2015-03-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinations of therapeutic agents for treating cancer
US7291936B1 (en) * 2006-05-03 2007-11-06 Robson John H Submersible electrical power generating plant
CN102731516B (zh) * 2011-04-07 2014-07-02 宁波天衡药业股份有限公司 一类具有抗肿瘤活性的喜树碱衍生物
WO2022140504A1 (en) * 2020-12-23 2022-06-30 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
DK0612248T3 (da) * 1991-11-15 2003-12-08 Smithkline Beecham Corp Præparat, der indeholder cisplatin og topotecan som antitumormiddel
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
IT1282673B1 (it) 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
IL127800A (en) 1996-08-19 2005-11-20 Bionumerik Pharmaceuticals Inc Highly lipophilic 7-substituted camptothecin derivatives and pharmaceutical compositions containing them
ATE216998T1 (de) 1999-03-09 2002-05-15 Sigma Tau Ind Farmaceuti Camptothecin-derivate mit antitumor-wirkung
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity

Also Published As

Publication number Publication date
DE602004018468D1 (de) 2009-01-29
ES2319293T3 (es) 2009-05-06
HK1089160A1 (zh) 2006-11-24
PL1603919T3 (pl) 2009-06-30
AR043620A1 (es) 2005-08-03
EP1603919B1 (en) 2008-12-17
DK1603919T3 (da) 2009-03-09
WO2004083214A1 (en) 2004-09-30
US20040018988A1 (en) 2004-01-29
KR101174112B1 (ko) 2012-08-16
US7105492B2 (en) 2006-09-12
US7351714B2 (en) 2008-04-01
JP2006520807A (ja) 2006-09-14
CA2517450C (en) 2011-06-14
TW200504076A (en) 2005-02-01
CA2517450A1 (en) 2004-09-30
CN100372855C (zh) 2008-03-05
CY1108890T1 (el) 2014-07-02
EP1603919A1 (en) 2005-12-14
US20060167033A1 (en) 2006-07-27
SI1603919T1 (sl) 2009-04-30
PT1603919E (pt) 2009-02-16
CN1761668A (zh) 2006-04-19
AU2004222044A1 (en) 2004-09-30
TWI341840B (en) 2011-05-11
KR20050107756A (ko) 2005-11-15
ATE417851T1 (de) 2009-01-15
AU2004222044B2 (en) 2010-02-25
BRPI0408380A (pt) 2006-03-21

Similar Documents

Publication Publication Date Title
JP4610743B2 (ja) 抗腫瘍活性を有するカンプトテシン誘導体
JP4791355B2 (ja) 抗腫瘍活性を有するカンプトテシンの７−イミノ誘導体
WO2012007619A1 (es) Proceso de obtención de derivados solubles en agua de 20(s)camptotecina como agentes antitumorales
HK1089160B (en) 7-imino derivatives of camptothecin having antitumor activity
KR101398591B1 (ko) 제암성 활성을 갖는 캠토테신 유도체
HK1031222B (en) Camptothecin derivatives having antitumor activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110628

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110721

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140729

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees